Table 1 Patients and tumours characteristics
From: A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
N° | Age (y) | FIGO | Grade | Mutation | Treatment | PSMA %DAB 1 | PSMA %DAB 2 | Interval between samples (months) | Relapse | Time of relapse after CT (months) | Death | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 46 | III | III | No | Surgery—ACT | 0.703 | – | – | Yes | 0.3 | No | 19.2 |
2 | 66 | III | III | BRCA1 | NACT—cytoreductive surgery—ACT | 0.005 | 0 | 3.3 | Yes | 18.0 | Yes | 70.8 |
3 | 83 | III | III | No | NACT—exploratory surgery—ACT | 0.109 | 0 | 3.0 | Yes | 7.6 | No | 64.7 |
4 | 58 | IV | III | Not available | NACT—exploratory surgery—ACT | 0.123 | 0 | 4.0 | Yes | 46.6 | No | 69.0 |
5 | 56 | III | III | No | Surgery—ACT | 0 | – | – | Yes | 32.0 | No | 84.7 |
6 | 62 | III | III | No | NACT—cytoreductive surgery—ACT | 0.009 | 0.003 | 2.9 | Yes | 7.9 | No | 61.0 |
7 | 63 | III | III | Not available | NACT—cytoreductive surgery—ACT | 0.017 | 0.081 | 3.7 | Yes | 4.7 | Yes | 37.5 |
8 | 61 | III | II | Not available | Surgery—ACT | 0.001 | – | – | Yes | 10.0 | Yes | 49.4 |
9 | 61 | III | III | No | Surgery—ACT | 0 | – | – | Yes | 1.0 | Yes | 17.8 |
10 | 61 | III | III | Not available | NACT—Progression, second line of ttt | 0.003 | – | – | Yes | 0.8 | Yes | 5.5 |
11 | 55 | III | III | No | NACT—cytoreductive surgery—ACT | 0.003 | 0 | 3.8 | Yes | 4.0 | Yes | 20.8 |
12 | 64 | III | III | No | NACT—cytoreductive surgery—ACT | 0 | 0.004 | 3.2 | Yes | 13.2 | Yes | 45.4 |
13 | 63 | III | III | Not available | Surgery—ACT | 0.028 | – | – | Yes | 1.1 | Yes | 8.5 |
14 | 73 | III | III | No | NACT—cytoreductive surgery—ACT | 0 | 0 | 4.1 | Yes | 4.8 | No | 53.9 |
15 | 48 | III | III | No | NACT—exploratory surgery—ACT | 0.008 | 0.033 | 4.1 | Yes | 3.0 | Yes | 16.6 |
16 | 74 | IV | III | No | NACT—cytoreductive surgery—ACT | 0.036 | 0 | 3.0 | Yes | 14.6 | Yes | 46.2 |
17 | 79 | III | III | No | NACT—cytoreductive surgery—ACT | 0.078 | 0.082 | 3.3 | Yes | 3.4 | No | 40.2 |
18 | 58 | III | III | No | NACT—cytoreductive surgery—ACT | 0.016 | 0.006 | 3.4 | Yes | 9.9 | Yes | 23.4 |
19 | 70 | III | III | No | NACT—exploratory surgery—ACT | 0.022 | 0.002 | 5.0 | Yes | 6.9 | No | 20.4 |
20 | 66 | III | III | BRCA2 | NACT—cytoreductive surgery—ACT | 0.014 | 0.018 | 4.9 | No | – | No | 91.0 |
21 | 48 | III | III | BRCA1 | NACT—cytoreductive surgery—ACT | 0.008 | 0 | 3.2 | Yes | 10.6 | Yes | 38.1 |
22 | 65 | III | III | Not available | NACT—exploratory surgery—ACT | 0.001 | 0 | 5.7 | Yes | 7.9 | No | 27.8 |
23 | 72 | III | II | No | NACT—cytoreductive surgery—ACT | 0 | 0.428 | 3.7 | Yes | 11.0 | Yes | 32.7 |
24 | 76 | III | III | No | NACT—cytoreductive surgery—ACT | 0.010 | 0.002 | 4.4 | Yes | 25.9 | Yes | 53.6 |
25 | 68 | III | III | Not available | NACT—cytoreductive surgery—ACT | 0.002 | 0.008 | 4.1 | Yes | 13.9 | Yes | 52.1 |
26 | 66 | III | III | No | NACT—cytoreductive surgery—ACT | 0.001 | 0.001 | 4.3 | Yes | 6.0 | Yes | 102.8 |
27 | 76 | III | III | Not available | NACT—exploratory surgery—ACT | 0.053 | 0.065 | 6.0 | Yes | 2.3 | Yes | 8.3 |
28 | 74 | III | III | No | NACT—cytoreductive surgery—ACT | 0 | 0.006 | 5.2 | Yes | 9.4 | Yes | 31.4 |
29 | 67 | IV | III | Not available | NACT—cytoreductive surgery—ACT | 0.016 | 0.554 | 5.3 | Yes | 3.4 | No | 27.9 |
30 | 74 | III | III | No | NACT—cytoreductive surgery—ACT | 0.019 | 0.049 | 4.7 | Yes | 18.2 | No | 47.7 |
31 | 82 | III | III | No | NACT—cytoreductive surgery—ACT | 0.027 | 0 | 4.4 | Yes | 8.6 | Yes | 33.3 |
32 | 83 | III | III | Not available | Surgery—ACT | 0.031 | – | – | Yes | 0.5 | Yes | 21.4 |